| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.1M | -27.3% | -35.6% |
| R&D Expense | $4.8M | -39.9% | -49.3% |
| SG&A Expense | $4.9M | +34.2% | +72.3% |
| Operating Income | -$7.6M | +12.0% | +13.8% |
| Net Income | -$7.4M | +12.2% | +14.0% |
| EPS (Basic) | -$0.07 | +22.2% | +58.8% |
| EPS (Diluted) | -$0.07 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $11.7M | -57.4% | -63.9% |
| Accounts Receivable | $387K | -27.3% | -87.7% |
| Current Assets | $25.8M | -16.3% | -30.7% |
| Total Assets | $31.6M | -22.3% | -29.4% |
| Current Liabilities | $15.5M | -19.4% | -7.5% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.6M | — | — |
| Capital Expenditures | $177K | — | — |
| Investing Cash Flow | -$6.9M | — | — |
| Financing Cash Flow | $16.8M | — | — |
| Free Cash Flow | -$20.8M | — | — |
| +22.2% |
| +58.8% |
| $18.4M |
| -18.4% |
| -5.4% |
| Stockholders' Equity | $13.2M | -27.1% | -47.8% |